NCT03581630 is a NA clinical trial of naltrexone/bupropion in Breast Cancer, sponsored by Gangnam Severance Hospital.

Who is sponsoring NCT03581630?

NCT03581630 is sponsored by Gangnam Severance Hospital.

What drugs are being tested in NCT03581630?

Interventions in NCT03581630: naltrexone/bupropion, Mediterranean Diet.

What condition does NCT03581630 study?

NCT03581630 studies Breast Cancer, Obesity, Overweight.

Is NCT03581630 still recruiting?

NCT03581630 is currently completed. Last updated 29 August 2018.

Last reviewed 2018-08-29 · How we verify

NCT03581630

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients

Completed NA Last updated 29 August 2018

What this trial tests

NA trial testing naltrexone/bupropion in Breast Cancer in 72 participants. Completed in 22 July 2018.

Timeline

29 July 2017

Primary endpoint
22 July 2018

22 July 2018

Quick facts

Lead sponsor	Gangnam Severance Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	72
Start date	29 July 2017
Primary completion	22 July 2018
Estimated completion	22 July 2018
Sites	1 location across South Korea

Drugs / interventions tested

naltrexone/bupropion
Mediterranean Diet

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Obesity — all drugs for Obesity →
Overweight — all drugs for Overweight →

Sponsor

Gangnam Severance Hospital

Who can join

Adults 20 to 65, female only, with Breast Cancer or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Obesity among breast cancer survivors is known to be associated with recurrence and other co-morbidities. However, there have been no studies on weight reduction program combining diet and anti-obesity drug for obese breast cancer survivors. The purpose of this randomized clinical trial is to examine the effects of Mediterranean Diet and naltrexone/bupropion treatment on inflammation and metabolic risk factors in overweight or obese breast cancer patients after breast cancer treatment.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The Mediterranean Diet: An Update of the Clinical Trials.
Finicelli M, Di Salle A, Galderisi U, Peluso G. · · 2022 · cited 105× · PMID 35889911 · DOI 10.3390/nu14142956
Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer.
Liang Y, Li H, Gan Y, Tu H. · · 2021 · cited 16× · PMID 34395421 · DOI 10.3389/fcell.2021.688953
Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial.
Cho AR, Choi WJ, Kwon YJ, Lee HS, et al · · 2020 · cited 10× · PMID 33061494 · DOI 10.2147/dmso.s269237
The Possible Influence of Mediterranean Diet on Extracellular Vesicle miRNA Expression in Breast Cancer Survivors.
Kwon YJ, Cho YE, Cho AR, Choi WJ, et al · · 2020 · cited 10× · PMID 32466456 · DOI 10.3390/cancers12061355
Circulating Polyamines and Metabolic Changes Following a Mediterranean Diet with or Without Naltrexone/Bupropion in Breast Cancer Survivors: An Exploratory Secondary Analysis.
Choi WJ, Lee YR, Lee YJ, Kwon YJ, et al · · 2026 · PMID 42197081 · DOI 10.3390/nu18101621

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03581630 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 29 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03581630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing